Background There continues to be a need to develop new pharmacological approaches for treating the common skin disease psoriasis. Human skin produces parathyroid hormone related peptide. This peptide is a potent inhibitor of epidermal cell growth. Objectives A programme was initiated to determine whether an agonist of this peptide's receptor, PTH (1-34), could be developed as a drug to treat psoriasis. Methods PTH (1-34) was formulated in Novasome A Ò cream. Fifteen adult patients with chronic plaque psoriasis who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The patients topically applied to a 25-cm 2 psoriatic lesion 0AE1 g of either Novasome A Ò cream or Novasome A Ò cream that contained 20 lg of PTH (1-34) twice a day for 2 months. At the end of the double-blind study, patients were enrolled in an open large area study. Ten patients applied PTH (1-34) (50 lg per 0AE1 g) once daily to their psoriatic lesions. The patients were evaluated for their global improvement and calcium metabolism. Results Novasome A Ò cream enhanced the percutaneous absorption of PTH (1-34) in human skin in comparison with formulations in propylene glycol or normal saline. Psoriatic lesions treated with PTH (1-34) showed marked improvement in scaling, erythema and induration. There was a 67AE3% improvement in the global severity score for the lesion treated with PTH (1-34) compared with the placebo-treated lesion, which only showed a 17AE8% improvement. Ten patients topically applied PTH (1-34) on all of their lesions in a stepwise manner. A Psoriasis Area and Severity Index score analysis of all the patients revealed improvement of 42AE6% (P < 0AE02). None of the patients experienced hypercalcaemia or hypercalciuria or developed any side-effect to the medication. Conclusions Patients who were resistant to at least one standard therapy for psoriasis had a remarkable improvement in their psoriasis when they applied PTH (1-34) to their lesion(s). No untoward toxicity was observed in any of the subjects. This pilot study suggests that topical PTH (1-34) is a safe and effective novel therapy for psoriasis.
inhibited in vitro keratinocyte proliferation and induced terminal differentiation and inhibited 3 H-thymidine incorporation into the epidermis in vivo similar to 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ]. [16] [17] [18] PTHrP peptides were also found to increase intracellular calcium of cultured keratinocytes 19 and antisense RNA for PTHrP-stimulated human keratinocyte growth. 20 In normal human skin, PTHrP is expressed in the maturing upper layers of the epidermis and not in the proliferating basal cells. 12 , 21 Juhlin et al. 21 observed that there was no expression of PTHrP in psoriatic skin and that PTHrP expression was restored in psoriatic skin that was treated with topical 1,25(OH) 2 D 3 .
Thus, there was an excellent rationale for developing PTH for the treatment of psoriasis. We formulated PTH (1-34) in a liposomal cream (Novasome A Ò ) that was found to enhance the percutaneous absorption of PTH (1-34) in vitro, and conducted a clinical trial to determine the safety and efficacy of topical PTH (1-34) for treating plaque psoriasis.
Materials and methods

Percutaneous absorption of 125 I-PTH (1-34)
Human PTH (1-34) (Bachem, King of Prussia, PA, U.S.A.) was iodinated with 125 I 2 8 and formulated in propylene glycol, normal saline or Novasome A Ò cream 22 (containing 65AE5% H 2 O, 25% ethoxydiglycol, 8% glycerol dilaurate, 4% propylene glycol dicaprylate ⁄ dicaprate, 1AE5% cholesterol and 1% cetearyl alcohol and cetearyl glucoside; IGI Inc., Buena Vista, NJ, U.S.A.). These formulations containing 1 lg 125 I-PTH (1-34) were applied to surgically obtained adult abdominal human epidermis in a Franz cell and the 125 I-PTH (1-34) recovered in the receptor medium in the lower chamber for 24 h, as previously described.
22,23
Double-blinded self-controlled evaluation of the efficacy and safety of topically administered PTH for the treatment of psoriasis Fifteen adult patients (10 men and five women; mean age 56 years, range 25-74; 14 white and one black) who had chronic plaque psoriasis and had failed to respond satisfactorily to at least one of the standard treatments for psoriasis signed our Institution Review Board's approved consent form. Each patient underwent prescreening to exclude patients with kidney stones, hypercalcaemia (serum calcium level > 10AE5 mg dL )1 ) or hypercalciuria (24-h urine calcium ⁄ creatinine > 0AE35). Patients on systemic or topical therapy for psoriasis stopped therapy for at least 30 and 14 days, respectively. Patients who were on medications that interfered with calcium metabolism were also excluded from the study. 24 Two symmetrically comparable psoriatic plaques were identified for the trial. The patients applied in a randomized doubleblinded manner to a 25-cm 2 lesion 0AE1 g of either Novasome A Ò cream or the Novasome A Ò cream that contained 20 lg of PTH (1-34) (UCB Bioproducts, Brussels, Belgium) twice a day for 2 months, using a plastic syringe that had 0AE1-mL gradations. Clinical assessment of severity of the psoriatic lesions was performed every 2 weeks, as previously described. 24, 25 Every 2 weeks blood and urine were collected and photographs were taken. 25, 26 At the end of the study three punch skin biopsies (0AE4 cm) were taken from each treated lesion and also from a nonlesional area for histological analysis of paraffin sections. 24, 25, 27 Open trial to evaluate safety and efficacy of topical PTH Immediately following the double-blinded study, the patients were given an opportunity to enrol in an open large area study. Ten patients agreed to participate. The patients were instructed to apply the PTH (1-34) cream (50 lg per 0AE1 g) once a day for the first month on lesion(s) of 100 cm 2 , and then on all the lesions thereafter. A 25-cm 2 area received 0AE1 g of Novasome A
Ò cream daily and served as the control lesion. One patient with extensive involvement of his limbs and trunk applied 3 mg of PTH (1-34) cream over an area of 1500 cm 2 daily. The mean area of application was 280 cm 2 for all of the patients. The patients were evaluated at monthly intervals to assess blood and urine calcium and the response of the lesions to treatment using a Psoriasis Area and Severity Index (PASI) score. 24, 25, 28 Statistical evaluation of the human trials was by the Wilcoxon method.
Results
Percutaneous absorption of 125 I-PTH (1-34)
Less than 1% of the 125 I-PTH (1-34) that was dissolved in either normal saline or propylene glycol and applied to adult human epidermis was recovered in the lower
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chamber of the Franz cell after 24 h. Forty-five per cent of 125 I-PTH (1-34) that was formulated in Novasome A Ò cream and topically applied to adult human epidermis penetrated through the epidermis, and was recovered in the lower chamber after 24 h.
Safety and efficacy of topically administered PTH (1-34) in a double-blinded randomized placebo self-controlled trial
Fifteen patients topically applied to comparable lesions either PTH (1-34) formulated in Novasome A Ò or Novasome A Ò cream for 2 months. All of the enrolled patients completed the trial. The lesions that received the PTH (1-34) showed marked improvement in scaling (mean ± SEM 73AE3 ± 8AE4%, P < 0AE001), erythema (51AE4 ± 8AE8%, P < 0AE002) and induration (74AE2 ± 4AE7%, P < 0AE0005) ( Fig. 1 ). Sixty per cent of patients had complete clearing of their lesions and 85% had experienced at least partial improvement. The Novasome A Ò placebo-treated lesions showed significantly less improvement in scaling (mean ± SEM 30AE0 ± 10AE0%), erythema (8AE3 ± 6AE1%) and induration (11AE7 ± 5AE6%) (Fig. 1 ). This degree of improvement is typically observed for a psoriatic lesion that is treated with a hydrating placebo ointment or cream. 23, 25, 26, 29 The global severity scores showed a significant improvement of mean ± SEM 67AE3 ± 5AE8% for the lesion treated with PTH (1-34) compared with only 17AE8 ± 4AE6% (P < 0AE0005) for the lesion treated with placebo Novasome A Ò cream alone (Fig. 1 ). There were no serious adverse events. No allergic reactions or dermatitis were reported or observed. None of the patients experienced hypercalcaemia or hypercalciuria, or any other biochemical changes in liver or renal function. The serum calcium levels at the baseline visit and at the conclusion of the study were identical (9AE1 ± 0AE1 and 9AE1 ± 0AE1 mg dL )1 , respectively). The 24-h urine calcium levels at the baseline visit (140 ± 19 mg per day) and at the end of the study (130 ± 22 mg per day) were not statistically different, nor were the urine calcium ⁄ creatinine ratio levels at the baseline visit (0AE09 ± 0AE01) and at the conclusion of the study (0AE11 ± 0AE02). An evaluation of the skin biopsies revealed a marked decrease in epidermal thickness for the lesion treated with PTH (1-34) compared with the control lesion treated with Novasome A Ò cream (Fig. 2) . Immunohistochemical evaluation of PTH (1-34)-treated lesions showed restoration of the transglutaminase activity to the granular layer of the epidermis that was present in the unaffected skin from the same patients (Fig. 2D,F ) compared with the diffuse staining in the placebotreated lesion (Fig. 2E) . Ò cream during the double-blind phase of the study (mean ± SEM; *P < 0AE001, **P < 0AE002, ***P < 0AE0005). the exception of the 25-cm 2 lesion that served as the control site and received Novasome A Ò cream alone. There was a significant reduction in scaling, erythema and plaque thickness that was first observed after 2 weeks of therapy. A PASI score analysis of all of the patients revealed an overall PASI score improvement of 42AE6% (P < 0AE02; Fig. 3 ). One patient who had had intractable psoriasis for over a decade and had not responded to conventional therapies including topical Dovonex Ò and steroids experienced remarkable improvement in his psoriasis (95% improvement in PASI score) and went into almost complete remission after 11 months of therapy (Fig. 2) .
None of the patients experienced hypercalcaemia or hypercalciuria. The blood calcium levels at the baseline visit and the last visit (7 ± 4 months; mean ± SD) were 9AE1 ± 0AE1 and 9AE2 ± 0AE1 mg dL )1 , respectively.
The 24-h urine calcium levels at the baseline visit and the last visit were also not significantly different at 134AE3 ± 34AE2 and 86AE4 ± 19AE6 mg per day, respectively. The urine calcium ⁄ creatinine ratio levels at the baseline visit and the last visit were 0AE12 ± 0AE02 and 0AE09 ± 0AE02, respectively. The most sensitive indicator for any enhancement in calcium metabolism is the lowering of the serum intact PTH level. We did not observe any significant decreases in the serum intact PTH levels in the patients (34 ± 10 pg mL )1 at baseline and 36 ± 12 pg mL )1 at the last visit).
Discussion
Activated vitamin D analogues for the treatment of psoriasis have provided a new approach for treating this difficult disease. [18] [19] [20] [21] [23] [24] [25] [26] [28] [29] [30] [31] However, about 15% of patients develop dermatitis, and most patients develop a resistance to vitamin D analogues after 0AE5-1 year of therapy. 23, 28 There continues to be a need for a safe and effective topical treatment for psoriasis.
Psoriatic epidermis does not express PTHrP and therefore it is reasonable either to restore PTHrP production or to treat psoriatic skin cells with a PTH-1 receptor agonist. The PTH-1 receptor agonist PTH (1-34) was found to be a potent inhibitor of epidermal proliferation and inducer of terminal differentiation in vitro and in vivo. [16] [17] [18] [19] [20] 32 Thus, it was reasoned that it might be useful for treating psoriasis.
One of the major stumbling blocks in developing PTH (1-34) for topical application for psoriasis was that it was a peptide. To date, there has been no successful development of a peptide for topical application to treat skin disease. Peptide drugs are usually given by injection or intranasally. Novasome A Ò cream is a nonionic stable liposome preparation that has previously been shown to enhance percutaneous absorption of polypeptides and other substances in rodent skin. 22 We observed that this Novasome A Ò cream markedly enhanced by > 40% the percutaneous absorption of PTH (1-34) in human skin in vitro. It was also possible that the daily topical application of the peptide PTH (1-34) could potentially cause dermal sensitization. However, topical application of PTH (1-34) for 2 and 3 months on SKH 1 hairless mice and guinea pigs, respectively, did not reveal any allergic response or other untoward side-effects on the skin (unpublished results). These favourable preclinical studies prompted us to conduct a pilot clinical trial to determine the safety and efficacy of PTH (1-34) for the treatment of psoriasis. When compared with the Novasome A Ò placebotreated lesions, the lesions receiving PTH showed dramatic decreases in scaling, erythema and plaque thickness. A histological analysis of the skin revealed a marked decrease in the thickness of the epidermis and a decrease in the lymphocytic infiltrate within the epidermis (Fig. 2) . In addition, the abnormal diffuse distribution of transglutaminase, a marker for epidermal differentiation, that was observed in the placebo-treated lesions, was restored to the upper granular layer of the lesions treated with PTH (1-34) and was similar in distribution to that in the unaffected normal skin of the same patient. These results suggest that PTH (1-34) not only decreased the hyperproliferative activity of the psoriatic lesion, but also restored epidermal differentiation towards normal.
We initially used PTH (1-34) at 20 lg per 0AE1 g twice daily because we were concerned that the peptide would be rapidly metabolized in the skin and therefore not be as effective if applied only once a day. However, for the convenience of the patients in our open trial we increased the dose by 150% and applied PTH (1-34) at 50 lg per 0AE1 g of Novasome A Ò cream once daily. Daily PTH (1-34) treatment was very effective in improving scaling, erythema and plaque thickness when compared with the placebo-treated lesion. Some patients, who had > 60% of their body involved with psoriasis, were topically applying as much as 3 mg of PTH (1-34) daily. Neer et al. 33 reported that the subcutaneous injection of only 20 lg of PTH (1-34) once a day caused hypercalciuria and transient hypercalcaemia in some patients who were being treated for osteoporosis. We were initially concerned that if even a small percentage of topical PTH (1-34) were absorbed through the epidermis into the dermal capillary bed it could cause hypercalcaemia or hypercalciuria. However, none of the patients experienced any significant deviation in either their 24-h urine calcium or serum calcium. One patient received topically more than 100 times the amount of PTH (1-34) that caused hypercalciuria and hypercalcaemia when given subcutaneously to patients with osteoporosis. 33 This is further supported by the fact that the serum intact PTH levels [the assay does not recognize PTH (1-34), only intact natural PTH (1-84)] did not decrease, which is also a strong indicator that little if any topical PTH (1-34) entered into the bloodstream to have calcaemic activity. There was no evidence of dermatitis or skin sensitization due to the topical application of this peptide. We did not observe any resistance to therapy for up to 1 year: this may offer another advantage for using PTH (1-34) for the treatment of psoriasis.
Our observation that PTH (1-34) was both safe and effective for treating psoriasis suggests that the development of PTH-1 receptor agonists is a reasonable new therapeutic approach for treating this enigmatic disease. The cost of these peptides is similar to that of active vitamin D compounds, again suggesting the feasibility of their development as a treatment for psoriasis.
